Yes, we strongly recommend it
However, existing research still faces issues such as insufficient reliability in demonstrating clinical causal relationships, overreliance on animal models, and inadequate elucidation of underlying mechanisms
Unless we assign a different scoring weight under these exceptions, for the CY 2026 performance period/2028 MIPS payment year, the scoring weights are as follows: 30 percent for the quality performance category
Cost considerations Pharmaceutical semaglutide (Wegovy): $1,300-1,500/month without insurance Insurance may cover (varies) Patient assistance programs available Research semaglutide: $150-300/month No insurance No patient assistance User assumes risk Research cagrilintide: $200-400/month Not prescription available yet Higher cost due to limited availability Total CagriSema combination cost (research chemicals): $350-700/month Both peptides at full dose Significant investment Compare to bariatric surgery ($15,000-25,000 upfront) Budget planning: Year 1 (titration + maintenance): $4,200-8,400 Ongoing maintenance: $350-700/month Consider reducing to maintenance doses May need 12-24+ months total Use our peptide cost calculator to budget protocols
SSRP Institute
Health care providers and MIPS eligible clinicians collect this electronic health information for patient care, and PHAs use the information for public health purposes such as tracking a disease, initiating contact tracing, or pinpointing the source of a disease or outbreak of foodborne illness
